Literature DB >> 26752677

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib.

Yoon Jin Cha1, Byoung Chul Cho2, Hye Ryun Kim2, Hye-Jeong Lee3, Hyo Sup Shim4.   

Abstract

Histologic changes can be involved in resistance to anticancer drugs. Transformation to small cell lung carcinoma (SCLC) following treatment with EGFR tyrosine kinase inhibitors has been reported in patients with EGFR-mutant lung adenocarcinoma. Herein, we report a case of ALK-rearranged lung adenocarcinoma with SCLC-like histology in a metastatic abdominal nodule that was resistant to crizotinib therapy.
Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaplastic lymphoma kinase; Crizotinib; Lung adenocarcinoma; Resistance; Small cell lung carcinoma

Mesh：

Substances：

Year:  2015        PMID： 26752677     DOI： 10.1016/j.jtho.2015.12.097

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  27 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement.

Authors:  Na Liu; Jingjing Wang; Xiao Fu; Xiaoqiang Zheng; Huan Gao; Tao Tian; Zhiping Ruan; Yu Yao
Journal:  Cancer Biol Ther       Date:  2019-09-27       Impact factor: 4.742

Review 3.  Unintentional weight loss: what radiologists need to know and what clinicians want to know.

Authors:  Sanjay Rao; Elias George Kikano; Daniel Arnold Smith; Ezgi Guler; Sree Harsha Tirumani; Nikhil H Ramaiya
Journal:  Abdom Radiol (NY)       Date:  2021-01-01

Review 4.  Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.

Authors:  Solange Peters; Stefan Zimmermann
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

Review 5.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

Review 6.  Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.

Authors:  M Drizou; E A Kotteas; N Syrigos
Journal:  Clin Transl Oncol       Date:  2017-01-04       Impact factor: 3.405

Review 7.  Histologic transformation in lung cancer: when one door shuts, another opens.

Authors:  Yuki Sato; Go Saito; Daichi Fujimoto
Journal:  Ther Adv Med Oncol       Date:  2022-10-14       Impact factor: 5.485

8.  A Tale of Two Histologies: Dissecting the Biology of Lineage Transformation in Lung Cancer.

Authors:  Catherine B Meador; Christine M Lovly
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

9.  Histologic transformation of non-small-cell lung cancer in brain metastases.

Authors:  Meng Jiang; Xiaolong Zhu; Xiao Han; Haiyan Jing; Tao Han; Qiang Li; Xiao Ding
Journal:  Int J Clin Oncol       Date:  2018-11-16       Impact factor: 3.402

Review 10.  The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.

Authors:  Yating Chen; Wenjie Guo; Junsheng Fan; Yuqing Chen; Xiaoli Zhang; Xin Chen; Peng Luo
Journal:  Cancer Manag Res       Date:  2017-12-07       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.